Roche Palo Alto LLC

University of California

N.v. Organon

David George Putman

Counde O'Yang

Michael Soth

David Garrett Loughhead

Olivier Dasse

Sanja Novakovic

Derk J Hogenkamp

Edward R Whittemore

Xao-Fa Lin

Mark S Jensen

Enantiomerically pure S-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associated with central nervous system using the compounds and pharmaceutical compositions.

Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use

Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH inhibitor, and their uses therof.

Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

[object Object]

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to said heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

Heterocyclic GABAA subtype selective receptor modulators

The invention provides compounds of the formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein, n, X, Y, R, R, R, Rand Rare as defined herein. The subject compounds are useful for treatment of 5-HT6 receptor antagonist-mediated diseases. Also provides are methods for preparing, compositions comprising, and methods for using the subject compounds.

Growing community of inventors

Stow, MA, United States of America

David George Putman